Equities research analysts expect Merck & Co., Inc. (NYSE:MRK) to report sales of $10.89 billion for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Merck & Co., Inc.’s earnings. The highest sales estimate is $11.01 billion and the lowest is $10.82 billion. Merck & Co., Inc. posted sales of $10.33 billion in the same quarter last year, which suggests a positive year over year growth rate of 5.4%. The firm is expected to issue its next earnings report on Friday, October 26th.
According to Zacks, analysts expect that Merck & Co., Inc. will report full-year sales of $42.36 billion for the current year, with estimates ranging from $42.24 billion to $42.59 billion. For the next financial year, analysts expect that the business will report sales of $43.14 billion per share, with estimates ranging from $42.17 billion to $43.95 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Merck & Co., Inc..
Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.03. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The business had revenue of $10.47 billion for the quarter, compared to analyst estimates of $10.28 billion. During the same period in the previous year, the business posted $1.01 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year.
Several research analysts have weighed in on the stock. Bank of America upped their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, July 30th. Jefferies Financial Group restated a “hold” rating and set a $59.00 price target on shares of Merck & Co., Inc. in a report on Sunday, July 15th. BMO Capital Markets restated a “buy” rating and set a $70.00 price target on shares of Merck & Co., Inc. in a report on Sunday, July 22nd. TheStreet upgraded shares of Merck & Co., Inc. from a “c+” rating to a “b-” rating in a report on Friday, June 8th. Finally, Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $69.00 price target for the company in a report on Thursday, June 7th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and an average target price of $66.24.
In other Merck & Co., Inc. news, insider Sanat Chattopadhyay sold 29,208 shares of the firm’s stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the completion of the sale, the insider now owns 70,675 shares of the company’s stock, valued at approximately $4,608,010. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Rita A. Karachun sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $65.01, for a total value of $325,050.00. The disclosure for this sale can be found here. Insiders sold 406,365 shares of company stock valued at $25,829,990 over the last quarter. Corporate insiders own 0.32% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. Clearwater Capital Advisors LLC acquired a new stake in shares of Merck & Co., Inc. during the first quarter worth $103,000. SRS Capital Advisors Inc. increased its position in shares of Merck & Co., Inc. by 208.4% in the first quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock worth $108,000 after purchasing an additional 1,340 shares during the period. Santori & Peters Inc. bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth $110,000. Taylor Wealth Management Partners bought a new position in shares of Merck & Co., Inc. in the second quarter worth $110,000. Finally, Creative Financial Designs Inc. ADV increased its position in shares of Merck & Co., Inc. by 155.2% in the second quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock worth $111,000 after purchasing an additional 1,114 shares during the period. 73.08% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. traded up $0.07, hitting $66.07, on Tuesday, according to Marketbeat Ratings. 7,439,672 shares of the company were exchanged, compared to its average volume of 8,021,469. The company has a current ratio of 1.33, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a fifty-two week low of $52.83 and a fifty-two week high of $66.99. The firm has a market capitalization of $177.95 billion, a P/E ratio of 16.60, a PEG ratio of 2.27 and a beta of 0.80.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 5th. Shareholders of record on Monday, September 17th will be paid a $0.48 dividend. This represents a $1.92 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date of this dividend is Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.24%.
About Merck & Co., Inc.
Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.
Featured Article: Penny Stocks, What You Need To Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.